Hashimoto's thyroiditis in children and adolescents: at presentation and during long-term follow up

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 432-458-Thyroid Autoimmunity
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-454
Hae Sang Lee*1 and Jin Soon Hwang2
1Ajou University School of Medicine, suwon, AK, South Korea, 2Ajou Univ School of Med, Suwon City, South Korea
Objective: Hashimoto’s thyroiditis (HT) is the most common cause of goiter and acquired hypothyroidism in children and adolescents. The aim of this study was to evaluate the clinical manifestations of HT leading to referral in children and adolescents, in addition to disease course and long-term outcome.

Methods: The clinical and laboratory data of 153 patients with HT at presentation and long-term outcome were retrospectively evaluated using patient records.

Results: At diagnosis the patient ages ranged from 2.1 to 16.1 years (median 10.8 years) and female/male ratio was 139/14. The complaint at the time of hospital presentation was goiter in 71.9% of the patients. Other reasons for referral were clinical symptoms of hypothyroidism (2.6%) and findings on work-up for an unrelated problem (20.9%) or for high-risk groups (2.6%). At baseline, 47.1% (n=72) of the patients were euthyroid, whereas 31.4% (n=48) had subclinical hypothyroidism, 14.4% (n=22) of subjects were evaluated as hypothyroid. Out of 153 patients, 11 were diagnosed with hashitoxicosis. From these 153 patients, the analysis was performed to those 133 patients in whom follow-up examinations over at least 6 months were available. Mean follow-up was 3.5 years. Nine of the 58 subjects, who were initially euthyroid developed subclinical or overt hypothyroidism during the follow-up period and were started on thyroid medication.

Conclusions: Thyroid function tests should be repeated periodically to detect progression to hypothyroidism in initially euthyroid patients as well as reversibility of hypothyroidism.

Nothing to Disclose: HSL, JSH

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm